Sometimes the best cancer treatment idea is not “hit harder,” but “stop letting the tumor hide behind the curtains.” That is the tidy little trick at the heart of this new TROPHAMET trial: pair a familiar chemotherapy, methotrexate, with an immune checkpoint drug, avelumab, and see whether the immune system can help finish the job without making a mess of everything else.
Gestational trophoblastic tumors, or GTT, are rare tumors that grow from placental-type cells after a pregnancy event, often after a molar pregnancy. Placental cells are normally remarkable little housebuilders. They help set up shop in the uterus and know how to negotiate with the immune system so pregnancy can happen. Very polite. Very diplomatic. But when those cells turn cancerous, that same talent for immune negotiation can become a problem. The tumor may act like a guest who was invited for tea and then quietly moved into the garage.
The hCG Smoke Alarm
One unusual thing about these tumors is that doctors can often track them with a blood marker called human chorionic gonadotropin, or hCG. That is the same hormone pregnancy tests detect. In GTT care, hCG is less “congratulations” and more “the smoke alarm is still chirping.”
Low-risk GTT is usually very treatable. Standard single-agent chemotherapy, often methotrexate or dactinomycin, cures many patients, and backup treatments work very well when the first drug fails. The catch is that first treatment does not always do the whole job. In the TROPHAMET paper, the authors note that single-agent chemotherapy gets cure rates around 70% in this low-risk setting. That is good, but if you are the person needing second-line therapy, “good on average” feels about as comforting as a screen door in a snowstorm.
Methotrexate is the old workhorse here. It interferes with folate metabolism, which fast-growing cells need to make DNA. Folinic acid is alternated in the regimen to help normal cells recover. Think of methotrexate as weeding the garden, and folinic acid as reminding the tomatoes that nobody was trying to pick a fight with them.
Enter Avelumab, the Immune System’s Hall Monitor
Avelumab blocks PD-L1, a protein tumors can use to press the brakes on immune attack. PD-L1 is basically the tumor saying, “Nothing to see here, officer,” while wearing a fake mustache. Avelumab tries to peel off the mustache.
This approach made biological sense because trophoblastic tumors often express immune checkpoint molecules, and earlier trials suggested avelumab could help some patients with chemotherapy-resistant disease. TROPHAMET asked a bolder question: why wait until methotrexate fails? Why not combine the garden weeder with the hall monitor right away?
In this phase 1/2 nonrandomized trial, 27 women with low-risk GTT received avelumab plus methotrexate as first-line therapy. Twenty-six were assessable for efficacy. The main success measure was hCG normalization that allowed treatment to stop. The result was striking: 96.2% achieved successful hCG normalization, and after a median follow-up of 41 months, no relapses were observed. Among patients with childbearing potential who wanted pregnancy, 13 of 14 later conceived.
That last point matters. A cancer treatment that works but burns down future fertility is not exactly a tidy victory, especially for a disease tied so closely to pregnancy. Here, fertility preservation is not a decorative footnote. It is part of the whole story.
Small Trial, Big Raised Eyebrow
Now, put the kettle down before we declare a new universal standard. This was a small, nonrandomized study. There was no head-to-head comparison against methotrexate alone. Rare cancer trials often have to work with small numbers because, inconveniently, rare diseases do not show up in neat stadium-sized crowds. Still, small trials can point to something worth testing properly.
Safety also looked manageable. There was one dose-limiting toxicity, grade 3 sepsis related to a central venous catheter. Six patients had grade 2 or higher immune- or treatment-related adverse events, and nearly all resolved, except one case of grade 2 dysthyroidism. No grade 4 or higher events were reported. That is encouraging, though immune side effects deserve long-term respect. The immune system is wonderful, but once you wake it up, it sometimes starts reorganizing the pantry.
Why This Could Matter
If larger comparative studies confirm these findings, this combination could reduce the number of patients who need salvage chemotherapy, shorten the emotional slog of watching hCG levels, and give clinicians a sharper tool for patients at higher risk of methotrexate resistance. It also fits a broader movement in GTT research: using immunotherapy not only as a last-ditch rescue rope, but as a planned part of treatment.
For patients, the practical dream is simple: cure the tumor, avoid unnecessary extra chemotherapy, preserve fertility when possible, and get back to life without the hCG smoke alarm beeping every time you try to relax.
That is not flashy science fiction. That is medicine doing what you hope it does: adding soap to the water when water alone sometimes leaves the pan greasy.
References
-
You B, Lotz JP, Descargues P, et al. Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial. JAMA Oncology. 2026. https://doi.org/10.1001/jamaoncol.2026.1697
-
Mangili G, Sabetta G, Cioffi R, et al. Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN). Cancers. 2022;14(11):2782. PMCID: PMC9179472. https://doi.org/10.3390/cancers14112782
-
Baas IO, Westermann AM, You B, Bolze PA, Seckl M, Ghorani E. Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm. Gynecologic and Obstetric Investigation. 2024;89:230-238. https://doi.org/10.1159/000533972
-
Cheng H, Zong L, Kong Y, et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. The Lancet Oncology. 2021;22:1609-1617. https://doi.org/10.1016/S1470-2045(21)00460-5
-
Chin A. Methotrexate for gestational choriocarcinoma: a paradigm shift in oncology. Nature Reviews Endocrinology. 2023;19:501. https://doi.org/10.1038/s41574-023-00874-9
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.